BENRALIZUMAB (Fasenra®)

Clinical Indication

For treating relapsing or refractory eosinophilic granulomatosis with polyangiitis

Comments

In line with NICE TA1096.

Date of classification

September 2025

Red

Medicines which should be prescribed only in a specialist setting usually within a secondary or tertiary care service. NB: Some highly specialised RED medicines e.g. injectable treatments for cancer are not included on the LLR APC website list.